Your session is about to expire
← Back to Search
Thrombectomy System
CAPERE Thrombectomy System for Arteriovenous Graft Thrombosis (AVATR Trial)
N/A
Waitlist Available
Led By Sebastian Mafeld, MD
Research Sponsored by Vascular Medcure, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Dialysis patients with clinical signs, symptoms and presentation consistent with acute thrombosis; onset of symptoms ≤ 14 days
Dialysis patients who are ≥ 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up open
Awards & highlights
AVATR Trial Summary
This study is evaluating whether a new device can remove blood clots from a patient's blood vessels.
Eligible Conditions
- Arteriovenous Graft Thrombosis
AVATR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAVATR Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ intraoperative
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intraoperative
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Primary Endpoint (Effectiveness)
Safety Evaluation
Secondary outcome measures
30-Day Patency Rate
Clinical Success
Device Safety
+2 moreAVATR Trial Design
1Treatment groups
Experimental Treatment
Group I: AVATR-TorontoExperimental Treatment1 Intervention
Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
Find a Location
Who is running the clinical trial?
Vascular Medcure, Inc.Lead Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled
Medtronic EndovascularLead Sponsor
68 Previous Clinical Trials
14,946 Total Patients Enrolled
Sebastian Mafeld, MDPrincipal InvestigatorUniversity Health Network Toronto General
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger